Background The Kassena-Nankana District of northern Ghana lies in the African “meningitis belt” where epidemics of meningococcal meningitis have been reoccurring every eight to 12 years for the last 100 years. The dynamics of meningococcal colonisation and disease are incompletely understood, and hence we embarked on a long-term study to determine how levels of colonisation with different bacterial serogroups change over time, and how the patterns of disease relate to such changes. Methods and Findings Between February 1998 and November 2005, pharyngeal carriage of Neisseria meningitidis in the Kassena-Nankana District was studied by twice-yearly colonisation surveys. Meningococcal disease was monitored throughout the eight-year study period, and patient isolates were compared to the colonisation isolates. The overall meningococcal colonisation rate of the study population was 6.0%. All culture-confirmed patient isolates and the majority of carriage isolates were associated with three sequential waves of colonisation with encapsulated (A ST5, X ST751, and A ST7) meningococci. Compared to industrialised countries, the colonising meningococcal population was less constant in genotype composition over time and was genetically less diverse during the peaks of the colonisation waves, and a smaller proportion of the isolates was nonserogroupable. We observed a broad age range in the healthy carriers, resembling that of meningitis patients during large disease epidemics. Conclusions The observed lack of a temporally stable and genetically diverse resident pharyngeal flora of meningococci might contribute to the susceptibility to meningococcal disease epidemics of residents in the African meningitis belt. Because capsular conjugate vaccines are known to impact meningococcal carriage, effects on herd immunity and potential serogroup replacement should be monitored following the introduction of such vaccines.
References
[1]
Greenwood B (1999) Manson lecture. Meningococcal meningitis in Africa. Trans R Soc Trop Med Hyg 93: 341–353.
[2]
Lapeyssonnie L (1963) La méningite cérébro-spinale en Afrique. Bull World Health Organ 28(SUPPL): 1–114.
[3]
World Health Organization (1998) Control of epidemic meningococcal disease. World Health Organization practical guidelines. 2nd Edition. Geneva: World Health Organization. 84 p.
[4]
World Health Organization (2000) Detecting meningococcal meningitis epidemics in highly-endemic African countries. Wkly Epidemiol Rec 75: 306–309.
[5]
Yazdankhah SP, Caugant DA (2004) Neisseria meningitidis: An overview of the carriage state. J Med Microbiol 53: 821–832.
[6]
World Health Organization (2005) Enhanced surveillance of epidemic meningococcal meningitis in Africa: A three-year experience. Wkly Epidemiol Rec 80: 313–320.
[7]
Zhu P, van der EA, Falush D, Brieske N, Morelli G, et al. (2001) Fit genotypes and escape variants of subgroup III during three pandemics of epidemic meningitis. Proc Natl Acad Sci U S A 98: 5234–5239.
[8]
Maiden MC, Bygraves JA, Feil E, Morelli G, Russell JE, et al. (1998) Multilocus sequence typing: A portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U S A 95: 3140–3145.
[9]
Taha MK, Achtman M, Alonso JM, Greenwood B, Ramsay M, et al. (2000) Serogroup W135 meningococcal disease in Hajj pilgrims. Lancet 356: 2159.
[10]
Nyarko P, Wontuo P, Nazzar A, Phillips J, Ngom P, et al. (2002) Navrongo DSS Ghana. Population, health and survival at INDEPTH sites. Volume 1. Accra (Ghana): INDEPTH. Available at: http://www.indepth-network.net/dss_site_？profiles/navrongo. Accessed: 13 February 2007.
[11]
Binka FN, Ngom P, Phillips JF, Adazu K, MacLeod BB (1999) Assessing population dynamics in a rural African society: The Navrongo demographic surveillance system. Journal of Biosocial Science 31: 375–391.
[12]
Gagneux S, Hodgson A, Ehrhard I, Morelli G, Genton B, et al. (2000) Microheterogeneity of serogroup A (subgroup III) during an outbreak in northern Ghana. Trop Med Int Health 5: 280–287.
[13]
Taha MK (2000) Simultaneous approach for nonculture PCR-based identification and serogroup prediction of . J Clin Microbiol 38: 855–857.
[14]
Bennett DE, Mulhall RM, Cafferkey MT (2004) PCR-based assay for detection of capsular serogroups 29E, X, and Z. J Clin Microbiol 42: 1764–1765.
[15]
Morelli G, Malorny B, Muller K, Seiler A, Wang JF, et al. (1997) Clonal descent and microevolution of Neisseria meningitidis during 30 years of epidemic spread. Mol Microbiol 25: 1047–1064.
[16]
Ala'Aldeen DA, Neal KR, Ait-Tahar K, Nguyen-Van-Tam JS, English A (2000) Dynamics of meningococcal long-term carriage among university students and their implications for mass vaccination. J Clin Microbiol 38: 2311–2316.
[17]
Simpson EH (1949) Measurement of diversity. Nature 163: 688.
[18]
Grundmann H, Hori S, Tanner G (2001) Determining confidence intervals when measuring genetic diversity and the discriminatory abilities of typing methods for microorganisms. J Clin Microbiol 39: 4190–4192.
[19]
Williams RL (2000) A note on robust variance estimation for cluster-correlated data. Biometrics 56: 645–646.
[20]
Hodgson A (2002) Meningococcal meningitis in northern Ghana: Epidemiological and clinical features, risk factors, survival and sequelae. Basel: University of Basel. 119 p. [dissertation].
[21]
Nicolas P, Decousset L, Riglet V, Castelli P, Stor R, et al. (2001) Clonal expansion of sequence type (ST-)5 and emergence of ST-7 in serogroup A meningococci, Africa. Emerg Infect Dis 7: 849–854.
[22]
Gagneux S, Wirth T, Hodgson A, Ehrhard I, Morelli G, et al. (2002) Clonal groupings in serogroup X Neisseria meningitidis. Emerg Infect Dis 8: 462–466.
[23]
Gagneux SP, Hodgson A, Smith TA, Wirth T, Ehrhard I, et al. (2002) Prospective study of a serogroup X Neisseria meningitidis outbreak in northern Ghana. J Infect Dis 185: 618–626.
[24]
Leimkugel J, Forgor AA, Gagneux S, Pfluger V, Flierl C, et al. (2005) An outbreak of serotype 1 meningitis in northern Ghana with features that are characteristic of meningitis epidemics. J Infect Dis 192: 192–199.
[25]
Yazdankhah SP, Kriz P, Tzanakaki G, Kremastinou J, Kalmusova J, et al. (2004) Distribution of serogroups and genotypes among disease-associated and carried isolates of from the Czech Republic, Greece, and Norway. J Clin Microbiol 42: 5146–5153.
[26]
Forgor AA, Leimkugel J, Hodgson A, Bugri A, Dangy JP, et al. (2005) Emergence of W135 meningococcal meningitis in Ghana. Trop Med Int Health 10: 1229–1234.
[27]
Caugant DA, Kristiansen BE, Froholm LO, Bovre K, Selander RK (1988) Clonal diversity of from a population of asymptomatic carriers. Infect Immun 56: 2060–2068.
[28]
Maiden MC (2004) Dynamics of bacterial carriage and disease: Lessons from the meningococcus. Adv Exp Med Biol 549: 23–29.
[29]
Jolley KA, Kalmusova J, Feil EJ, Gupta S, Musilek M, et al. (2000) Carried meningococci in the Czech Republic: A diverse recombining population. J Clin Microbiol 38: 4492–4498.
[30]
Claus H, Maiden MC, Wilson DJ, McCarthy ND, Jolley KA, et al. (2005) Genetic analysis of meningococci carried by children and young adults. J Infect Dis 191: 1263–1271.
[31]
Cartwright KA, Stuart JM, Jones DM, Noah ND (1987) The Stonehouse survey: Nasopharyngeal carriage of meningococci and . Epidemiol Infect 99: 591–601.
[32]
Blackwell CC, Weir DM, James VS, Todd WT, Banatvala N, et al. (1990) Secretor status, smoking and carriage of . Epidemiol Infect 104: 203–209.
[33]
Caugant DA, Hoiby EA, Magnus P, Scheel O, Hoel T, et al. (1994) Asymptomatic carriage of in a randomly sampled population. J Clin Microbiol 32: 323–330.
[34]
Cartwright K (1995) Meningococcal carriage and disease. In: Cartwright K, editor. Meningococcal disease. Chichester (United Kingdom): John Wiley & Sons. pp. 115–147.
[35]
Greenwood BM, Bradley AK, Cleland PG, Haggie MH, Hassan-King M, et al. (1979) An epidemic of meningococcal infection at Zaria, Northern Nigeria. 1. General epidemiological features. Trans R Soc Trop Med Hyg 73: 557–562.
[36]
Moore PS (1992) Meningococcal meningitis in sub-Saharan Africa: A model for the epidemic process. Clin Infect Dis 14: 515–525.
[37]
Griffiss JM (1982) Epidemic meningococcal disease: Synthesis of a hypothetical immunoepidemiologic model. Rev Infect Dis 4: 159–172.
[38]
Tikhomirov E, Santamaria M, Esteves K (1997) Meningococcal disease: Public health burden and control. World Health Stat Q 50: 170–177.
[39]
Borrow R, Goldblatt D, Andrews N, Richmond P, Southern J, et al. (2001) Influence of prior meningococcal C polysaccharide vaccination on the response and generation of memory after meningococcal C conjugate vaccination in young children. J Infect Dis 184: 377–380.
Maiden MC, Stuart JM (2002) Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 359: 1829–1831.
[42]
Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E (2003) Herd immunity from meningococcal serogroup C conjugate vaccination in England: Database analysis. BMJ 326: 365–366.
[43]
Maiden MC, Spratt BG (1999) Meningococcal conjugate vaccines: New opportunities and new challenges. Lancet 354: 615–616.
